Chongqing Lummy Pharmaceutical News

Laimei Pharmaceutical (300006): Plans to subscribe for REPLICOR shares to strengthen the layout of the hepatitis B drug field, innovate, and continue to advance R&D and transformation

安信證券Aug 8, 2021 00:00

Lai Mei Pharmaceutical (300006): due to the impact of collection, the report is lower than expected and the development of new business is still orderly.

申萬宏源研究Aug 2, 2021 00:00

Laimei Pharmaceutical (300006): The profitability of companies that raised a fixed increase of 1,084 million yuan from Zhongheng Group and others is expected to be optimized

安信證券Feb 18, 2021 00:00

Lai Mei Pharmaceutical (300006): focus on further improvement of Q3 performance in Oncology and Ophthalmology in 2020

安信證券Oct 28, 2020 00:00

Laimei Pharmaceutical (300006): An innovative drug development platform focusing on oncology and ophthalmology, Laimei is poised to launch

安信證券Sep 17, 2020 00:00

Laimei Pharmaceutical (300006): strategic layout several hundred hospitals of ophthalmology medicine Aier help to release volume

西南證券May 7, 2019 00:00

Laimei Pharmaceutical (300006): Revenue growth is in line with expectations, specialty drugs are growing rapidly

西南證券Apr 25, 2019 00:00

Lai Mei Pharmaceutical (300006): deducting non-stable growth in performance and increasing the proportion of specialist drug contribution

西南證券Apr 9, 2019 00:00

Lai Mei Pharmaceutical (300006): high barrier product line moat policy immunity performance increases rapidly

西南證券Apr 3, 2019 00:00

Lai Mei Pharmaceutical (300006) in-depth report: continuous volume of specialty drugs brings performance flexibility.

國海證券Apr 3, 2019 00:00

Laimei Pharmaceutical (300006): Xinweige's sales volume may exceed expectations, and the company's development has entered the fast track

西南證券Mar 28, 2019 00:00

Laimei Pharmaceutical (300006) Quarterly Report Review: The Performance of Featured Specialty Pharmaceuticals Has Improved Significantly

東吳證券Nov 1, 2016 00:00

Laimei Pharmaceutical (300006): Prospects for improved performance can be expected

東吳證券Nov 1, 2016 00:00

Laimei Pharmaceutical (300006) Quarterly Report Review: Third-quarter results increased 233% year-on-year to benefit from high growth in specialty drugs

廣證恆生Oct 31, 2016 00:00

Laimei Pharmaceutical (300006) Quarterly Report Review: The Share of Specialty Specialty Drugs Has Increased, and Revenue Structure Continues to Be Optimized

西南證券Oct 31, 2016 00:00

[Dongwu Securities] Laimei Pharmaceutical: Featured specialty drug distribution, marked improvement in performance

東吳證券Oct 31, 2016 00:00

[Guangzheng Hang Seng Consulting] Laimei Pharmaceutical Review Report: Third quarter results increased 233% year-on-year, benefiting from high growth in specialty drugs

廣證恆生諮詢Oct 30, 2016 00:00

[Southwest Securities] Laimei Pharmaceutical: The share of specialty drugs has increased, and the revenue structure continues to be optimized

西南證券Oct 30, 2016 00:00

Laimei Pharmaceutical (300006) Research Report: Further Promotion of Big Variety Strategy Expected to Accelerate Company Performance

中投證券Sep 26, 2016 00:00

莱美药业(300006)：专科药放量进入提速期的拐点型黑马

廣證恆生Aug 16, 2016 00:00